The latest news: Publication in Nature Communications Confirms DRD2 as Target of ONC201 That is what we thought but it is nice to have proof! RESULTS OF PHASE II CLINICAL TRIAL OF ONCOLYTIC HERPES VIRUS G47? IN PATIENTS WITH GLIOBLASTOMA Amazing results. For recurrent gbm, 1 year survival of 92% compared to 15% historical controls. BrainTumor Co-Payment Assistance Program Status: Almost closed to new applicants - Call first
